- Home
- HSCS vs GLMD Comparison
HSCS vs GLMD Comparison
Compare HSCS & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | GLMD |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 6.6M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HSCS | GLMD |
|---|---|---|
| Price | $3.52 | $0.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.20 | N/A |
| AVG Volume (30 Days) | 55.7K | ★ 82.7K |
| Earning Date | 03-12-2026 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,669.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.01 | $0.73 |
| 52 Week High | $6.47 | $3.50 |
Technical Indicators
Market Signals| Indicator | HSCS | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 42.18 |
| Support Level | $3.08 | $0.76 |
| Resistance Level | $3.70 | $0.88 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 77.33 | 54.60 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.